Effects of Apatinib combined with Temozolomide on levels of sPD-1 and sPD-L1 in patients with drug-resistant recurrent glioblastoma

IF 2.2 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Clinics Pub Date : 2024-01-01 DOI:10.1016/j.clinsp.2024.100376

Ren Zhao Kuang , Jun Wang , Yuan Chuan Wang , Xiao Ping Tang

{"title":"Effects of Apatinib combined with Temozolomide on levels of sPD-1 and sPD-L1 in patients with drug-resistant recurrent glioblastoma","authors":"Ren Zhao Kuang , Jun Wang , Yuan Chuan Wang , Xiao Ping Tang","doi":"10.1016/j.clinsp.2024.100376","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>This study aimed to explore the effects of Apatinib combined with Temozolomide (TMZ) on the levels of Soluble PD-1 (sPD-1) and Soluble Programmed Death-1 Ligand (sPD-L1) in patients with drug-resistant recurrent Glioblastoma (GB).</p></div><div><h3>Study design</h3><p>A total of 69 patients with recurrent GB from September 2020 to March 2022 were recruited and assigned to the control group (n = 34) and observation group (n = 35) according to different treatment options after tumor recurrence. The control group was treated with TMZ, and the observation group was treated with Apatinib combined with TMZ. Levels of sPD-1 and spd-l1, clinical efficacy, survival time and adverse reactions were observed and compared between the two groups.</p></div><div><h3>Results</h3><p>General data including gender, age, body mass index, and combined diseases indicated no statistical significance between groups (p > 0.05). Before the intervention, sPD-1 and sPD-L1 levels were not significantly different in the two groups (p > 0.05). After interventions, levels of PD-1 and sPD-L1 levels decreased significantly (p < 0.05). The objective remission rate and clinical benefit rate of the observation group were higher and overall survival and progression-free survival were longer than those of the control group (p < 0.05). No significant difference was observed in major adverse reactions among patients (p > 0.05).</p></div><div><h3>Conclusions</h3><p>Apatinib combined with TMZ is safe and effective in the treatment of recurrent GB. The combined application of the two can reduce the levels of sPD-1 and sPD-L1, which has important clinical application value.</p></div>","PeriodicalId":10472,"journal":{"name":"Clinics","volume":"79 ","pages":"Article 100376"},"PeriodicalIF":2.2000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S180759322400053X/pdfft?md5=9572741e604f5cbecafa38de2589f9ea&pid=1-s2.0-S180759322400053X-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S180759322400053X","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

This study aimed to explore the effects of Apatinib combined with Temozolomide (TMZ) on the levels of Soluble PD-1 (sPD-1) and Soluble Programmed Death-1 Ligand (sPD-L1) in patients with drug-resistant recurrent Glioblastoma (GB).

Study design

A total of 69 patients with recurrent GB from September 2020 to March 2022 were recruited and assigned to the control group (n = 34) and observation group (n = 35) according to different treatment options after tumor recurrence. The control group was treated with TMZ, and the observation group was treated with Apatinib combined with TMZ. Levels of sPD-1 and spd-l1, clinical efficacy, survival time and adverse reactions were observed and compared between the two groups.

Results

General data including gender, age, body mass index, and combined diseases indicated no statistical significance between groups (p > 0.05). Before the intervention, sPD-1 and sPD-L1 levels were not significantly different in the two groups (p > 0.05). After interventions, levels of PD-1 and sPD-L1 levels decreased significantly (p < 0.05). The objective remission rate and clinical benefit rate of the observation group were higher and overall survival and progression-free survival were longer than those of the control group (p < 0.05). No significant difference was observed in major adverse reactions among patients (p > 0.05).

Conclusions

Apatinib combined with TMZ is safe and effective in the treatment of recurrent GB. The combined application of the two can reduce the levels of sPD-1 and sPD-L1, which has important clinical application value.

查看原文本刊更多论文

阿帕替尼联合替莫唑胺对耐药复发性胶质母细胞瘤患者sPD-1和sPD-L1水平的影响

本研究旨在探讨阿帕替尼联合替莫唑胺（TMZ）对耐药复发性胶质母细胞瘤（GB）患者可溶性PD-1（sPD-1）和可溶性程序性死亡-1配体（sPD-L1）水平的影响。研究设计从2020年9月至2022年3月共招募69例复发性GB患者，根据肿瘤复发后的不同治疗方案将其分为对照组（34例）和观察组（35例）。对照组接受TMZ治疗，观察组接受阿帕替尼联合TMZ治疗。结果性别、年龄、体重指数、合并疾病等一般资料显示组间差异无统计学意义（P >0.05）。干预前，两组的 sPD-1 和 sPD-L1 水平无明显差异（p > 0.05）。干预后，PD-1和sPD-L1水平明显下降（p < 0.05）。与对照组相比，观察组的客观缓解率和临床获益率更高，总生存期和无进展生存期更长（p <0.05）。结论阿帕替尼联合TMZ治疗复发性GB安全有效。两者联合应用可降低sPD-1和sPD-L1的水平，具有重要的临床应用价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinics 医学-医学：内科

CiteScore

4.10

自引率

3.70%

发文量

129

审稿时长

52 days

期刊介绍： CLINICS is an electronic journal that publishes peer-reviewed articles in continuous flow, of interest to clinicians and researchers in the medical sciences. CLINICS complies with the policies of funding agencies which request or require deposition of the published articles that they fund into publicly available databases. CLINICS supports the position of the International Committee of Medical Journal Editors (ICMJE) on trial registration.